A positive analyst take on Dynavax Technologies' (NASDAQ: DVAX) stock lit the biotech company's shares on fire Tuesday. The enthusiastic analyst is JMP Securities' Roy Buchanan, who initiated coverage on Dynavax stock early Tuesday morning. Buchanan's recommendation is market outperform (buy, in other words) at a price target of $22 per share.